HomeCompareOCEL vs PLD

OCEL vs PLD: Dividend Comparison 2026

OCEL yields 72.93% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $4.70M in total portfolio value· pulled ahead in Year 9
10 years
OCEL
OCEL
● Live price
72.93%
Share price
$2.74
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.20M
Annual income
$325,655.22
Full OCEL calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — OCEL vs PLD

📍 PLD pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCELPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCEL + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCEL pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCEL
Annual income on $10K today (after 15% tax)
$6,198.72/yr
After 10yr DRIP, annual income (after tax)
$276,806.94/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $3,761,309.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCEL + PLD for your $10,000?

OCEL: 50%PLD: 50%
100% PLD50/50100% OCEL
Portfolio after 10yr
$3.56M
Annual income
$2,538,190.20/yr
Blended yield
71.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

OCEL
No analyst data
Altman Z
-38.0
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCEL buys
0
PLD buys
0
No recent congressional trades found for OCEL or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCELPLD
Forward yield72.93%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$1.20M$5.91M
Annual income after 10y$325,655.22$4,750,725.19
Total dividends collected$1.03M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: OCEL vs PLD ($10,000, DRIP)

YearOCEL PortfolioOCEL Income/yrPLD PortfolioPLD Income/yrGap
1$17,993$7,292.62$11,241$540.96+$6.8KOCEL
2$31,515$12,262.92$13,019$991.13+$18.5KOCEL
3$53,795$20,073.98$15,801$1,870.97+$38.0KOCEL
4$89,585$32,023.91$20,609$3,701.21+$69.0KOCEL
5$145,696$49,840.41$29,919$7,867.97+$115.8KOCEL
6$231,650$75,755.11$50,631$18,617.74+$181.0KOCEL
7$360,433$112,567.38$105,528$51,352.20+$254.9KOCEL
8$549,352$163,689.57$287,364$174,449.42+$262.0KOCEL
9← crossover$820,973$233,165.47$1,081,760$774,280.77$260.8KPLD
10$1,204,096$325,655.22$5,908,209$4,750,725.19$4.70MPLD

OCEL vs PLD: Complete Analysis 2026

OCELStock

Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases. Its leading product candidate is Zofin, an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs without the addition or combination of any other substance or diluent, which is in Phase I/II clinical trial to treat COVID-19. The company also provides independent education, advertising, and marketing services to medical and other healthcare, anti-aging, and regenerative service providers. It has a research and development agreement with the Centers for Disease Control and Prevention to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection; and an agreement with Oklahoma State University to evaluate Zofin for the treatment of respiratory diseases caused by virus infections of pandemic potential. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. was incorporated in 2011 and is headquartered in Miami, Florida.

Full OCEL Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this OCEL vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCEL vs SCHDOCEL vs JEPIOCEL vs OOCEL vs KOOCEL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.